Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03749447 · ClinicalTrials.gov registry record · Phase 3
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT03749447 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 270 participants.
The verdict
NCT03749447, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.
Interventions
- DRUG Bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2023-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03749447
The ClinicalTrials.gov registry entry for NCT03749447 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bardoxolone methyl is the first listed.
NCT03749447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03749447 about?
NCT03749447 is a clinical study titled "An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)". This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolon...
What is the current status of trial NCT03749447?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2019-03-08. Estimated completion is 2023-08-23.
What interventions are being tested in trial NCT03749447?
The interventions under investigation include: Bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT03749447?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.